-+ 0.00%
-+ 0.00%
-+ 0.00%

Sernova, Seraxis agree merger to form BetaNova Biotherapeutics

PUBT·09/08/2026 11:06:03
Listen to the news
Sernova, Seraxis agree merger to form BetaNova Biotherapeutics
  • Sernova Biotherapeutics agreed to merge with Seraxis to form BetaNova Biotherapeutics, a type 1 diabetes islet cell-replacement developer.
  • Post-close ownership is expected to be split roughly 50-50 between Sernova and Seraxis shareholders.
  • The deal is expected to close in November 2026, subject to shareholder approval.
  • Insider investors committed USD 10 million in a non-brokered convertible note financing tied to the transaction.
  • BetaNova plans to seek a Nasdaq listing in Q1 2027, subject to meeting listing requirements and approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9821737) on September 08, 2026, and is solely responsible for the information contained therein.